The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Long-term results from a phase Ib/II study of magrolimab plus rituximab in R/R iNHL
|
The 3-year results from a multicenter, phase Ib/II trial (NCT02953509), which investigated magrolimab combined with rituximab (M+R) in patients with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL), were published in Blood Advances by Mehta et al.1 A total of 46 patients with R/R B-cell NHL were enrolled in phase Ib and received a priming dose of 1 mg/kg magrolimab followed by magrolimab maintenance doses of 10, 20, 30, or 45 mg/kg. In phase II, based on the safety data from phase Ib, maintenance doses of 30 and 45 mg/kg magrolimab combined with 375 mg/m2 rituximab were explored. The primary endpoints included the incidence and severity of treatment-emergent adverse events (TEAEs) and objective response rate (ORR) of M+R combination.1 |
| Key learnings: |
|
At least one TEAE and treatment-related TEAE were reported in 100% and 95.7% of patients, respectively. Infusion-related reaction (60.9%), headache (52.2%), and fatigue (45.7%) were the most common any grade TEAEs. The combination of M+R was well tolerated long term, with no new TEAEs identified during the follow-up period and no treatment-related deaths. |
|
The M+R combination was associated with an ORR of 52.2%, with 30.4% of patients achieving a complete response. Among the responders, the median time to response was 1.8 months and the median duration of response was 15.9 months, indicating durable clinical benefit. |
|
Responses with M+R were comparable across patient subgroups regardless of progression of disease ≤24 months or prior lines of therapy, suggesting its applicability in heavily pre-treated populations. |
|
Median progression-free survival was 7.4 months and the median overall survival was not reached. |
|
The results highlight the potential of M+R in iNHL, particularly for patients with limited treatment options due to refractory disease. Future studies should consider investigating M+R with emerging immunotherapies, such as CAR T-cell therapy or bispecific T-cell engagers, to potentially improve patient outcomes without adding significant toxicity. |
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
